Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Regeneron Pharmaceuticals (NQ:REGN)

714.89 +5.79 (+0.82%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 589,042
Open 709.29
Bid (Size) 705.00 (40)
Ask (Size) 717.00 (80)
Prev. Close 709.10
Today's Range 708.36 - 717.99
52wk Range 476.49 - 821.11
Shares Outstanding 91,779,465
Dividend Yield 0.53%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Will Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There. ↗
The competition is far behind. 
Via The Motley Fool
News headline image
Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
-7.9%
-7.9%
1 Month
-7.8%
-7.8%
3 Month
-8.9%
-8.9%
6 Month
+8.7%
+8.7%
1 Year
+30.5%
+30.5%

More News

Read More
News headline image
Is This Biotech Stock a Buy After a Groundbreaking Approval? ↗
Via The Motley Fool
News headline image
5 Must-Read Analyst Questions From Regeneron’s Q1 Earnings Call
Via StockStory
Topics Earnings
Regeneron Pharmaceuticals (NASDAQ:REGN) Beats Q1 Estimates, But Stock Slips on Margin Headwinds and Manufacturing Glitch ↗
Via Chartmill
News headline image
Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Is Regeneron a Buy After the FDA Approved its Gene Therapy to Restore Hearing? ↗
Via The Motley Fool
News headline image
1 Cash-Producing Stock Worth Investigating and 2 Facing Headwinds
Via StockStory
News headline image
Regeneron Pharmaceuticals Analysts Cut Their Forecasts Following Q1 Earnings ↗
Via Benzinga
News headline image
REGN Q1 Deep Dive: Product Expansion Drives Growth, Margin Pressures Draw Scrutiny
Via StockStory
News headline image
3 Healthcare Stocks We Keep Off Our Radar
Via StockStory
News headline image
Why Regeneron (REGN) Shares Are Getting Obliterated Today
Via StockStory
Topics Artificial Intelligence World Trade
Exploring the top movers within the S&P500 index during today's session. ↗
Via Chartmill
These S&P500 stocks have an unusual volume in today's session ↗
Via Chartmill
News headline image
Regeneron (REGN) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
Which S&P500 stocks are moving on Wednesday? ↗
Via Chartmill
Wednesday's session: gap up and gap down stock in the S&P500 index ↗
Via Chartmill
News headline image
Regeneron (NASDAQ:REGN) Reports Strong Q1 CY2026
Via StockStory
News headline image
Regeneron Reports First Quarter 2026 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron (REGN) Q1 Earnings Report Preview: What To Look For
Via StockStory
Topics Artificial Intelligence
These S&P500 stocks are gapping in today's session ↗
Via Chartmill
News headline image
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
Via StockStory
Topics Artificial Intelligence
News headline image
Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Regeneron Pharmaceuticals publicly traded?
Yes, Regeneron Pharmaceuticals is publicly traded.
What exchange does Regeneron Pharmaceuticals trade on?
Regeneron Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Regeneron Pharmaceuticals?
The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market
What is the current price of Regeneron Pharmaceuticals?
The current price of Regeneron Pharmaceuticals is 714.89
When was Regeneron Pharmaceuticals last traded?
The last trade of Regeneron Pharmaceuticals was at 05/08/26 04:00 PM ET
What is the market capitalization of Regeneron Pharmaceuticals?
The market capitalization of Regeneron Pharmaceuticals is 65.61B
How many shares of Regeneron Pharmaceuticals are outstanding?
Regeneron Pharmaceuticals has 66B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.